Home > Journals > Minerva Endocrinologica > Past Issues > Articles online first > Minerva Endocrinologica 2020 Nov 19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Endocrinologica 2020 Nov 19

DOI: 10.23736/S0391-1977.20.03369-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Obesity and GLP-1

Alejandra PEREZ-MONTES DE OCA, Silvia PELLITERO , Manuel PUIG-DOMINGO

Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital and Research Institute, Autonomous University of Barcelona, Badalona, Spain


PDF


Obesity is an important public health issue that has been on the rise over the last decades. It calls for effective prevention and treatment. Bariatric surgery is the most effective medical therapy for weight loss in morbid obesity but we are in need for less aggressive treatments. Glucagon-likepeptide-1 receptor agonists are a group of incretin based drugs that have proven to be productive for obesity treatment. Through activation of the GLP-1 receptor they not only have an important role stimulating insulin secretion after meals, but with their extra-pancreatic actions, both peripheral and central, they also help reduce body weight by promoting satiety and delaying gastric emptying. Liraglutide in a dose of 3 mg is currently the only drug of this group that is approved by the FDA to treat obesity, with weight losses up to 8.5 kg in relatively short periods of time. Here we review the data so far collected of GLP-1 use for obesity with and without diabetes, including the recent data of oral semaglutide.


KEY WORDS: GLP-1; Incretin therapy; Obesity; Weight loss

top of page